1-11 of 11
Agnès Guerci, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Jean-Claude Chomel, PharmD, PhD, Marie Laure Bonnet, Nathalie Sorel, PhD, Ivan Sloma, PharmD, PhD, Alexis Proust, Annelise Bennaceur-Griscelli, MD, PhD, Delphine Rea, MD, PhD, Madalina Uzunov, M.D., Laurence Legros, MD, PhD, Shanti Ame, MD, Anne Marfaing-Koka, Agnès Guerci, MD, Philippe Rousselot, MD, PhD, Ali G Turhan, M.D., PhD
Journal: Blood
Blood (2012) 120 (21): 3726.
https://doi.org/10.1182/blood.V120.21.3726.3726
Published: 2012
Journal Articles

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Philippe Rousselot, MD, PhD, Luigina Mollica, MD, FRCPC, PhD, Gabriel Etienne, MD, PHD, Stephane Bouchet, Agnès Guerci, MD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony-Makhoul, MD, Valérie Coiteux, MD, Martine Gardembas, MD, Laurence Legros, MD, PhD, Lydia Roy, MD, Aude Charbonnier, MD, PhD, Caroline Dartigeas, MD, Jean-Michel Cayuela, PhD, Lambert Busque, MD, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Francois Guilhot, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3770.
https://doi.org/10.1182/blood.V120.21.3770.3770
Published: 2012
Journal Articles

Phosphorylation of Spleen Tyrosine Kinase (Syk) Appears to Be Related to the Blast Phase of Chronic Myeloid Leukemia

Céline Bourgne, Alexandre Janel, Jacques Chassagne, PhD, Chantal Rapatel, Olivier Tournilhac, MD, PhD, Agnès Guerci, MD, Frédérique Lioret, Aurélie Briançon, Juliette Berger, Mahchid Bamdad, Nathalie Boiret-Dupré, Marc G Berger, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4425.
https://doi.org/10.1182/blood.V120.21.4425.4425
Published: 2012
Journal Articles

Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk

Djamel Aggoune, Nathalie Sorel, PhD, Sanaa El Marsafy, MD, PhD, Marie Laure Bonnet, Denis Clay, Marie Claude Meunier, Karin Tarte, Olivier Herault, MD, PhD, Jorge Domenech, MD, PhD, Agnès Guerci, MD, Jean-Claude Chomel, PharmD, PhD, Ali G Turhan, M.D., PhD
Journal: Blood
Blood (2012) 120 (21): 908.
https://doi.org/10.1182/blood.V120.21.908.908
Published: 2012
Journal Articles

Flow Cytometry Detection of Intra-Cellular Tyrosine Kinase Inhibitors (TKI) Showed Variable Uptake in CML CD34+ Cells

Céline Bourgne, Mahchid Bamdad, Alexandre Janel, Frédéric Libert, Agnès Guerci, MD, Marie-Claude Gagnieu, Chantal Rapatel, Pascale Pigeon, Sylvie Pereira, Eric Hermet, MD, Pascale Cony Makhoul, Atchroue Johnson-Ansah, Jean Yves Cahn, MD, Denis Guyotat, Sébastien Trouillier, Juliette Berger, Nathalie Boiret-Dupré, Marc G Berger, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2747.
https://doi.org/10.1182/blood.V118.21.2747.2747
Published: 2011
Journal Articles

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, Joelle Guilhot, Francois Guilhot, Françoise Huguet, MD, Franck E. Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PhD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 603.
https://doi.org/10.1182/blood.V118.21.603.603
Published: 2011
Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Simone Boehrer, MD, Odile Beyne-Rauzy, MD, Thomas Prebet, M.D., Ph.D., Sophie Park, MD, PhD, Agnès Guerci, MD, Aspasia Stamatoulas, MD, MP Chaury, MD, Tony Jernival, Laurence Sanhes, MD, Gerard Tertian, MD, Stephane Cheze, MD, Eng-Mong Lim, Bachra Choufi, MD, Denis Caillot, MD, E. Wattel, MD, Jacques Delaunay, MD, Laurence Legros, MD, Fatiha Chermat, Françoise Isnard, MD, N. Cambier, MD, Borhane Slama, MD, Lydia Roy, MD, Gandhi Damaj, MD, Emmanuel Raffoux, MD, Francois Dreyfus, MD, Christian Récher, MD, Norbert Vey, MD, Sylvie Chevret, PhD, Pierre Fenaux, MD, PhD, Claude Gardin, MD
Journal: Blood
Blood (2010) 116 (21): 1880.
https://doi.org/10.1182/blood.V116.21.1880.1880
Published: 2010
Journal Articles

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Philippe Rousselot, MD, PhD, Stéphane Boucher, MD, PhD, Gabriel Etienne, MD, PhD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony Makhoul, MD, Valérie Coiteux, MD, Agnès Guerci, MD, Martine Gardembas, MD, Laurence Legros, MD, Lydia Roy, MD, Caroline Dartigeas, MD, Maud Janvier, MD, Christian Berthou, MD, Lambert Busque, MD, FRCPC, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Luigina Mollica, MD, FRCPC, PhD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3432.
https://doi.org/10.1182/blood.V116.21.3432.3432
Published: 2010
Journal Articles

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

Claude Gardin, MD, Thomas Prébet, MD, Krimo Bouabdallah, MD, Denis Caillot, MD, Agnès Guerci, MD, PhD, Emmanuel Raffoux, MD, Jean Pierre Marolleau, MD, Cecile Pautas, MD, Anne Banos, MD, Chantal Himberlin, MD, Anne-Laure Taksin, MD, Arnaud Pigneux, MD, PhD, Xavier Thomas, MD, PhD, Tony Jernival, Norbert Vey, Francois Dreyfus, MD, PhD, Sylvie Chevret, PhD, Herve Dombret, MD, PhD, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 844.
https://doi.org/10.1182/blood.V114.22.844.844
Published: 2009
Journal Articles

Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).

François Guilhot, MD, Claude Preudhomme, Joelle Guilhot, MSci, Francois-Xavier Mahon, MD, PhD, Franck Emmanuel Nicolini, MD, PhD, Francoise Rigual-Huguet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, PhD, Delphine Rea, MD, PhD, Valerie Coiteux, MD, Frederic Maloisel, MD, Martine Gardembas, MD, Claude-Eric Bulabois, MD, Marc G Berger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 340.
https://doi.org/10.1182/blood.V114.22.340.340
Published: 2009
Journal Articles

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Agnès Guerci, MD, Franck Nicolini, MD, Frederic Maloisel, MD, Selim Corm, MD, Laurence Legros, MD, Françoise Rigal-Huguet, MD, Philippe Rousselot, MD, Krimo Bouabdallah, MD, Martine Gardembas, MD, Anne Vekoff, MD, Jean-Jacques Kiladjian, MD, Martine Delain, MD, François-Xavier Mahon, MD, Claude Preudhomme, MD, Joelle Guilhot, BS, François Guilhot, MD
Journal: Blood
Blood (2005) 106 (11): 168.
https://doi.org/10.1182/blood.V106.11.168.168
Published: 2005